BioDelivery Sciences International (NASDAQ:BDSI) Trading Up 5.1%

Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) were up 5.1% on Thursday . The stock traded as high as $3.95 and last traded at $3.90, approximately 984,062 shares were traded during trading. An increase of 1% from the average daily volume of 973,723 shares. The stock had previously closed at $3.71.

Several research analysts have recently weighed in on BDSI shares. BidaskClub cut shares of BioDelivery Sciences International from a “sell” rating to a “strong sell” rating in a research report on Wednesday. Cantor Fitzgerald set a $8.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Friday, May 10th. ValuEngine cut shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Thursday. Finally, Zacks Investment Research raised shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a research report on Tuesday, May 21st. Two research analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. BioDelivery Sciences International presently has a consensus rating of “Hold” and a consensus price target of $6.20.

The stock’s 50-day moving average price is $4.19. The company has a debt-to-equity ratio of 1.90, a quick ratio of 2.57 and a current ratio of 2.88. The company has a market capitalization of $332.19 million, a P/E ratio of -5.18 and a beta of 0.48.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its earnings results on Monday, May 6th. The specialty pharmaceutical company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.03. BioDelivery Sciences International had a negative net margin of 42.09% and a negative return on equity of 43.40%. The company had revenue of $19.77 million for the quarter, compared to analysts’ expectations of $19.60 million. As a group, research analysts anticipate that BioDelivery Sciences International, Inc. will post -0.15 earnings per share for the current fiscal year.

In other BioDelivery Sciences International news, Director Healthcare Master Fun Broadfin sold 1,800,000 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $5.00, for a total value of $9,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Herm Cukier sold 30,285 shares of the company’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $5.07, for a total transaction of $153,544.95. Following the completion of the transaction, the chief executive officer now directly owns 66,666 shares in the company, valued at approximately $337,996.62. The disclosure for this sale can be found here. Insiders sold 2,429,743 shares of company stock worth $11,699,958 in the last ninety days. 8.94% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Emerald Advisers LLC increased its stake in BioDelivery Sciences International by 881.4% during the first quarter. Emerald Advisers LLC now owns 1,734,422 shares of the specialty pharmaceutical company’s stock worth $9,192,000 after purchasing an additional 1,557,692 shares during the period. Emerald Mutual Fund Advisers Trust increased its stake in BioDelivery Sciences International by 836.4% during the first quarter. Emerald Mutual Fund Advisers Trust now owns 1,556,947 shares of the specialty pharmaceutical company’s stock worth $8,252,000 after purchasing an additional 1,390,682 shares during the period. Millennium Management LLC increased its stake in BioDelivery Sciences International by 703.6% during the fourth quarter. Millennium Management LLC now owns 981,422 shares of the specialty pharmaceutical company’s stock worth $3,631,000 after purchasing an additional 859,292 shares during the period. ClariVest Asset Management LLC purchased a new stake in BioDelivery Sciences International during the first quarter worth about $2,571,000. Finally, Laurion Capital Management LP increased its stake in BioDelivery Sciences International by 128.5% during the first quarter. Laurion Capital Management LP now owns 573,638 shares of the specialty pharmaceutical company’s stock worth $3,040,000 after purchasing an additional 322,629 shares during the period. 56.85% of the stock is currently owned by institutional investors.

About BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Read More: The mechanics of the bid-ask spread in trading

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.